A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov

A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov

A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

This study is currently recruiting participants.

Verified March 2012 by University of Michigan Cancer Center

First Received on March 30, 2012.   Last Updated on April 16, 2012   History of Changes

Sponsor:	University of Michigan Cancer Center
Information provided by (Responsible Party):	Ronald Buckanovich, University of Michigan Cancer Center
ClinicalTrials.gov Identifier:	NCT01579812

  Purpose

The primary objective of this study is to determine if metformin administered as the time of traditional adjuvant chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at 18 months compared to controls.